Download Complete Issue (pdf 3800kb) - Academic Journals

More documents

Recommendations

Info

1914 Afr. J. Pharm. Pharmacol. Table 1 cont Jin X 30 2009 Wang X 31 2009 Zhang YH 32 2009 Heystek 33 2009 Li SQ 34 2008 Pei YH 35 2008 Zhang GH 36 2007 China UTI China NGU China UTI England PID China UTI China Female RTI China Urogential infections MFX 121 - 400 mg, po,qd × 10d SPFX 121 300 mg ,po,qd × 10d MFX 60 (0/60) - 400 mg, po, qd × 12d CLA 60 (0/60) 500 mg, po, qd × 12d MFX 40 (23/17) 39 ± 8 400 mg, iv, qd × 7d GAT 40 (24/16) 37 ± 9 400 mg, iv, qd × 7d MFX 232 (0/232) DOX/MTZ/CPFX 202 (0/202) 29.1 ± 7.2 28.5 ± 7.0 400mg,po, qd ×14d DOX 100 mg, bid × 14d + MTZ400 mg, tid × 14d + CPFX500 mg MFX 90 400 mg, po, qd × 10d LVFX 86 200mg,po,bid × 10d MFX 62 (0/62) 30.5 400mg,po,qd ×14d CPFX 50 (0/50) 200 mg, po, bid × 14d MFX 38 (26/12) 45 ± 13 400 mg, po, qd × 7d GAT 38 (25/13) 45 ± 12 200 mg, ivgtt, bid × 7d 93.4 (113/121) 92.6 (112/121) 63.3 (38/60) 48.3 (29/60) 87.5 (35/40) 85.0 (34/40) 96.5 (224/232) 98.0 (198/202) 94.4 (85/90) 86.0 (74/86) 66.1 (41/62) 40.0 (20/50) 60.5 (23/38) 63.2 (24/38) 95.1 (115/121) 95.9 (116/121) 95.7 (116/121) 96.7 (117/121) 9.1 (11/121) 9.1 (11/121) 81.7 (49/60) - 5.0 (3/60) 65.0 (39/60) - 0 (0/60) 95.0 (38/40) 77.5 (31/40) 5.0 (2/40) 92.5 (37/40) 76.9(30/39) 7.5 (3/40) - 93.5 (43/46) - 89.7 (35/39) 44.0 (151/343) 49.7 (162/326) 97.8 (88/90) 96.7 (87/90) 7.8 (7/90) 91.9 (79/86) 94.2 (81/86) 9.3 (8/86) 91.9 (57/62) 89.5 (51/57) 8.1 (5/62) 62.0 (31/50) 72.7 (32/44) - 86.8 (33/38) 91.3 (42/46) 2.6 (1/38) 89.5 (34/38) 92.0 (46/50) 5.3 (2/38)
Table 1. contd. Sun GQ 37 007 Ross 38 2006 Luo XM 39 2006 Luo JL 40 2006 Gao HY 41 2005 Tian YP 42 2005 Zhang WF 43 2004 China NGU England PID China UTI and RTI China China UTI China China Urogential infections Urogential infections Urogential mycoplasma infection Mu et al. 1915 MFX 45 (26/19) 28.3 ± 11 400 mg, po, qd × 12 ~ 14d 75.0 (33/44) 93.2 (41/44) 91.8 (45/49) 18.2 (8/44) AZI 41 (26/15) 27.36 ± 12 500 mg, po, qd × 12~14d 29.3 (12/41) 75.6 (31/41) 75.6 (31/41) 14.6 (6/41) MFX 384 (0/384) 30.1 ± 8.4 400 mg, po, qd × 14d 90.2(248/275) - 87.5 (49/85) 22.5 (85/378) OFLX/MT Z 365 (0/365) 30.5 ± 8.5 OFLX400 mg + MTZ500mg,po,bid ×14d 90.7(262/289) - 82.1 (46/56) 30.9(112/363 ) MFX 56 (0/56) 27.6 ± 3.1 400mg,po,qd×12d 78.6 (44/56) 91.1(51/56) - 12.5 (7/56) DOX 56 (0/56) 27.5 ± 2.0 1 pill, po, bid × 14d 51.8 (29/56) 76.8(43/56) - 73.2 (41/56) MFX 52 18 ~ 60 400 mg, po, qd × 14d 65.4 (34/52) 92.3 (48/51) 93.3 (56/60) 9.6 (5/52) GAT 50 200 mg, po, bid × 14d 64.0 (32/50) 90.0 (45/50) 88.5 (54/61) 10.0 (5/50) CPFX 48 200 mg, po, bid × 14d 41.7 (20/48) 64.6 (31/48) 57.9 (33/57) 10.4 (5/48) MFX 22 42.6 ± 10 Morning 400 mg + one placebo, evening two placebo, po × 7-14d 52.6 (10/19) 84.2 (16/19) 100.0 (14/14) 65.0 (13/20) LVFX 22 (1/43) 43.5 ± 17.7 200 mg, po, bid × 7-14d 47.1 (8/17) 82.4 (14/17) 72.7 (8/11) 40.9 (9/22) MFX 29 (41/17) 19 ~ 45 400 mg, po, qd × 7d 79.3 (23/29) 93.1 (27/29) 89.7 (26/29) 55.2 (16/29) THI 29 500 mg, po, tid × 7d 58.6 (17/29) 65.5 (19/29) 58.6 (17/29) 62.2 (18/29) MFX 43 400 mg, po, qd × 14d 74.4 (32/43) 95.3 (41/43) 90.7 (39/43) 9.3 (4/43) SPFX 43 (33/96) 29.6 200 mg, po, qd × 14d 65.1 (28/43) 90.7 (39/43) 88.4 (38/43) 11.6 (5/43) LVFX 43 200 mg, po, bid × 14d 53.5 (23/43) 69.8 (30/43) 67.4 (29/43) 16.3 (7/43) MFX 20 (1/19) 42 ± 13 Morning 400 mg + one placebo, evening two placebo, po × 7 - 14d 90.0 (8/20) 95.0 (19/20) 94.7 (18/19) 27.2 (6/22) LVFX 20 (1/19) 42 ± 14 200 mg, po, bid × 7 - 14d 85.0 (17/20) 90.0 (18/20) 100.0 (19/19) 27.2 (6/22) MFX: Moxifloxacin; LVFX: levofloxacin; AZI: azithromycin; OFLX: ofloxacin; MTZ: metronidazole; SPFX: sparfloxacin; GAT: gatifloxacin; CTRX: ceftriaxone sodium; CLA: clarithromycin; CPFX: ciprofloxacin; TRZ: terazosin; CAZ: ceftazidime; DOX: doxycycline; MINO: Minocycline; THI: thiamphenicol; UTI: urinary tract infections; NGU: non gonococcal urethritis; PID: pelvic inflammation disease; RTI: reproductive tract infection. patients with urinary tract infections (UTI), four pelvic inflammation disease (PID), five nongonococcal urethritis (NGU), four urogenital infections and one reproductive tract infection (RTI). Patients in the moxifloxacin group received moxifloxacin at dosage of 400 mg once a day (orally or intravenously), while the control group received the recommended dose of other antibiotics (according to different countries), such as levofloxacin, azithromycin, ofloxacin, metronidazole, sparfloxacin, gatifloxacin
Page 1 and 2: African Journal of Pharmacy and Pha
Page 3 and 4: Editors Sharmilah Pamela Seetulsing
Page 5 and 6: Electronic submission of manuscript
Page 7 and 8: Fees and Charges: Authors are requi
Page 9 and 10: Table of Contents: Volume 6 Number
Page 13 and 14: Minimum inhibitory concentration (M
Page 15 and 16: Kim et al. 1887 Table 4. Antimicrob
Page 17 and 18: Klevens RM, Morrison M A, Nadle J,
Page 19 and 20: Figure 1. Chemical structure of ten
Page 21 and 22: ng/ml by 4.9 ml blank plasma with 5
Page 23 and 24: Figure 5. Chromatogram of plasma sp
Page 25 and 26: Figure 7. Chromatogram of a healthy
Page 27 and 28: Figure 11. Chromatograms of standar
Page 31 and 32: Shatoor 1903 Figure 1. The effect o
Page 33 and 34: Heart rate (Beats/min.) 345 330 315
Page 35 and 36: Table 2. Percent of changes in hear
Page 37 and 38: heart rate on coronary flow and car
Page 39 and 40: Urinary tract infections are the mo
Page 41: Table 1. Study characteristics of i
Page 45 and 46: Study or Subgroup Cai SF 2003 Gao H
Page 47 and 48: Study or Subgroup Cai SF 2003 Gao H
Page 49 and 50: cure rate and clinical effective ra
Page 53 and 54: Table 1. The expression of KAI1 and
Page 57 and 58: Figure 2. Typical chromatograms of
Page 59 and 60: Excretion studies Figure 4 shows th
Page 63 and 64: Table 1. Statistical results of the
Page 65 and 66: ethinylestradiol /100 g levonorgest
Page 67 and 68: HO CH 2OH O OH OH OCH 2CH 2 OH Figu
Page 69 and 70: A B Figure 3. Bax positive cells of
Page 73 and 74: Table 1. Summary of specific reacti
Page 75 and 76: Figure 3. Effects of the sap of Jat
Page 79 and 80: Figure 1. A schematic diagram showi
Page 81 and 82: Chen et al. 1953 Figure 4. Concentr
Page 83 and 84: Figure 6. Representative photomicro
Page 85 and 86: shock. The features of PHC can expl
Page 87 and 88: Administration of single or repeate
Page 89 and 90: Table 1. Effects of green tea on SO
Page 91 and 92: Ozardali I, Bitiren M, Ali ZK, Zeri
Page 93 and 94:
EXPERIMENTAL PROCEDURE Materials an
Page 95 and 96:
Scavenging rate (%) Figure 1 Scaven
Page 97 and 98:
A D Figure 5 Figure Effects 5. of E
Page 99 and 100:
African Journal of Pharmacy and Pha
Page 101 and 102:
Figure 1. Level-spacing distributio
Page 103 and 104:
Number of cases Pattern Shi et al.
Page 105 and 106:
Page 107 and 108:
sodium was then dissolved in 1000 m
Page 109 and 110:
Concentration (ppm) Concentration (
Page 111 and 112:
various contagious diseases such as
Page 113 and 114:
Table 3. Antibacterial MIC (µg/ml)
Page 115 and 116:
Table 5. Contd. 1/5 14.7 ± 0.6 39.
Page 117 and 118:
UPCOMING CONFERENCES 6th European C
Page 119:
show all

Download Complete Issue (pdf 3800kb) - Academic Journals

Create successful ePaper yourself

Delete template?

Save as template?